James Breitmeyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript November 9, 2023 Oncternal Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.15. Operator: Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to […]

The FDA has granted fast track designation to the dual-acting androgen receptor inhibitor ONCT-534 for the treatment of patients with relapsed/refractory, metastatic castration-resistant prostate cancer that is resistant to approved androgen receptor pathway inhibitors.

By Dean Seal Oncternal Therapeutics said regulators have granted its fast-track designation for ONCT-534, a treatment for patients with relapsed or...

SAN DIEGO, Oct. 26, 2023 -- Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and...

(2023-09-07 | NDAQ:ONCT) Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board